Radiation therapy can treat prostate cancer with curative intent by delivering ionizing radiation to the prostate and selected surrounding tissues while limiting dose to the bladder, rectum, urethra and other normal structures. The two main local radiation approaches are external-beam radiation therapy (EBRT), delivered from a machine outside the body, and brachytherapy, in which radioactive sources are placed inside the prostate. The correct radiation plan depends on risk group, stage, urinary function, prostate anatomy, life expectancy and whether androgen-deprivation therapy (ADT) should be added.
Radiation is a standard curative local treatment for clinically significant localized and locally advanced prostate cancer. Modern EBRT usually uses IMRT or VMAT with image guidance and may be delivered conventionally, with moderate hypofractionation, or in selected patients with ultra-hypofractionation/SBRT. Brachytherapy can be delivered as permanent low-dose-rate seeds or temporary high-dose-rate catheters. Low- and favorable intermediate-risk disease may be treated with radiation alone, while unfavorable intermediate- and high-risk disease commonly requires radiation plus ADT, with brachytherapy boost considered in selected patients with good urinary function.
01How Does Radiation Therapy Treat Prostate Cancer?
Radiation damages the DNA of cancer cells
Ionizing radiation deposits energy inside tissue.
That energy damages DNA directly and indirectly, making it difficult for prostate-cancer cells to continue dividing.
Normal tissues can also be affected, which is why modern prostate radiotherapy is planned around both:
- the target volume that needs an effective cancer dose;
- and the organs at risk that should receive as little unnecessary dose as possible.
What structures are close enough to matter?
The prostate sits:
- below the bladder;
- in front of the rectum;
- around the upper urethra;
- below the seminal vesicles;
- and near the neurovascular structures involved in erectile function.
Those relationships explain the major toxicity domains:
- urinary irritation or obstruction;
- rectal and bowel symptoms;
- erectile dysfunction;
- and, with pelvic treatment, additional exposure to surrounding normal tissues.
How does modern EBRT shape the dose?
Current EAU guidance recognizes intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT) with image-guided radiation therapy (IGRT) as standard external-beam approaches.
Computerized treatment planning changes the intensity and angle of multiple beams so that their high-dose region overlaps in the prostate while dose to the rectum and bladder is constrained.
Why is image guidance needed?
The prostate does not occupy exactly the same position every day.
Its position can change with:
- bladder filling;
- rectal gas or stool;
- breathing and body setup;
- and internal organ motion.
IGRT uses imaging before or during treatment to confirm that the target remains aligned with the radiation plan.
What are fiducial markers?
Small radiopaque markers can be placed inside the prostate before EBRT so imaging systems can identify the gland precisely during treatment.
Not every radiation platform requires fiducials because some systems use cone-beam CT, MRI guidance or other image-registration methods.
What is a rectal spacer?
A temporary hydrogel or similar spacer can be placed between the prostate and rectum in selected patients to increase physical separation and reduce rectal dose.
Spacer use is not mandatory for every patient and has its own procedural costs and risks, so it should be considered within the overall radiation plan rather than treated as an automatic requirement.
Modern prostate radiation is a planning problem as much as a dose problem. The same prescription can produce different toxicity if target localization, motion management and organ-at-risk constraints are not handled well.
02What Types of Radiation Therapy Are Used for Prostate Cancer?
External-beam radiation is delivered from outside the body
The most common definitive external-beam methods are:
- IMRT — beam intensity changes across multiple treatment angles;
- VMAT — the treatment machine rotates around the patient while beam shape and intensity change continuously;
- SBRT / ultra-hypofractionated radiation — a small number of highly precise, larger-dose fractions;
- proton-beam therapy — particle radiation that deposits dose differently from x-rays but remains a form of EBRT.
The dedicated next guide covers External-Beam Radiation Therapy for Prostate Cancer in greater technical detail.
What is conventional fractionation?
Conventional fractionation divides the total radiation dose into many smaller daily treatments.
Historically, localized prostate radiation was often delivered over roughly seven to nine weeks.
What is moderate hypofractionation?
Moderate hypofractionation gives a larger dose per treatment over fewer sessions.
Current EAU recommendations include schedules such as:
- 60 Gy in 20 fractions over about four weeks;
- or 70 Gy in 28 fractions over about six weeks.
AUA/ASTRO guidance strongly supports moderate hypofractionation for low- and intermediate-risk patients who elect EBRT and also supports it for appropriate high-risk patients.
What is SBRT?
Stereotactic body radiation therapy is an ultra-hypofractionated form of EBRT.
The treatment uses very precise image guidance and larger doses per fraction, commonly delivered over approximately five treatments in selected protocols.
EAU guidance allows ultra-hypofractionated schedules in selected favorable intermediate-risk patients with attention to urinary function.
Is proton therapy a separate cure from standard radiation?
No.
Proton therapy is an external-beam radiation modality with different physical dose deposition.
It can reduce dose to some surrounding tissues in specific plans, but current prostate-cancer evidence does not establish proton therapy as universally superior to high-quality photon IMRT/VMAT for cancer control or patient-reported outcomes.
What is low-dose-rate brachytherapy?
Low-dose-rate (LDR) brachytherapy places multiple small radioactive seeds permanently inside the prostate.
The seeds emit radiation over weeks to months and gradually become inactive.
LDR brachytherapy is a standard option for appropriately selected low-risk and favorable intermediate-risk patients with good urinary function.
What is high-dose-rate brachytherapy?
High-dose-rate (HDR) brachytherapy uses temporary catheters placed through the perineum into the prostate.
A high-activity radioactive source travels through the catheters for a planned period, delivers the dose, and is then removed.
No radioactive source remains in the body after HDR treatment.
Can brachytherapy be combined with EBRT?
Yes.
For selected unfavorable intermediate-risk, high-risk or locally advanced prostate cancers with good urinary function, LDR or HDR brachytherapy can be used as a boost in addition to EBRT.
The goal is to escalate dose inside the prostate while EBRT treats a broader surrounding volume.
This approach can improve biochemical control in selected higher-risk disease, but the dose escalation also increases the risk of urinary toxicity such as urethral stricture or obstructive symptoms.
Brachytherapy is not simply “stronger radiation.” It is a different dose-delivery geometry. Its success depends heavily on prostate size, urethral anatomy, baseline urinary symptoms and implant quality.
03How Is Radiation Treatment Selected by Prostate-Cancer Risk Group?
The radiation modality and the need for ADT change as cancer risk increases
A treatment plan should integrate:
- Grade Group;
- PSA;
- clinical stage;
- MRI and other staging information;
- percentage and location of biopsy involvement;
- urinary function;
- prostate volume;
- life expectancy and comorbidity;
- and patient priorities.
What is the radiation role in low-risk disease?
Radiation can cure low-risk prostate cancer.
However, suitable low-risk disease is often managed initially with active surveillance because treatment may be unnecessary.
When a low-risk patient chooses active treatment, accepted radiation options include modern hypofractionated EBRT or brachytherapy in appropriately selected patients.
Routine ADT is generally not needed.
What about favorable intermediate-risk disease?
AUA/ASTRO guidance lists:
- dose-escalated hypofractionated EBRT;
- permanent LDR seed implantation;
- or temporary HDR prostate implantation;
as appropriate radiation options for low- or favorable intermediate-risk disease.
Routine ADT is generally not recommended for favorable intermediate-risk disease when high-quality definitive radiation is used.
How does unfavorable intermediate-risk disease change the plan?
The risk of microscopic extension and recurrence is higher.
Current AUA/ASTRO guidance recommends adding short-course ADT for approximately four to six months when unfavorable intermediate-risk disease is treated with radiation.
Possible local radiation strategies include:
- dose-escalated EBRT;
- moderately hypofractionated EBRT;
- or EBRT plus an LDR or HDR brachytherapy boost in selected patients.
What is the standard pattern for high-risk localized disease?
High-risk prostate cancer usually requires combined-modality treatment.
Current guideline frameworks recommend:
- high-quality EBRT;
- long-course ADT;
- and in selected patients, brachytherapy boost or treatment of additional pelvic volumes.
AUA/ASTRO guidance describes long-course ADT as approximately 18 to 36 months, while EAU guidance commonly recommends two to three years with definitive EBRT in high-risk localized disease.
When are pelvic lymph nodes irradiated?
Pelvic nodal radiation is not routine for low-risk or ordinary intermediate-risk disease.
It may be considered in selected high-risk or node-positive patients when the predicted risk of microscopic pelvic nodal disease is sufficient to justify the larger treatment field.
Does locally advanced prostate cancer still receive curative radiation?
Yes, selected cN0M0 and cN1M0 disease can be treated with curative-intent radiation as part of multimodal therapy.
As stage and nodal risk rise, treatment can include:
- prostate and sometimes pelvic EBRT;
- long-term ADT;
- and, in specific very-high-risk or node-positive settings, additional systemic intensification such as abiraterone according to current guideline criteria.
Why is ADT added to radiation?
Androgen-deprivation therapy reduces androgen signaling that supports prostate-cancer growth.
Combined with radiation, it can:
- improve local and systemic disease control in higher-risk disease;
- reduce recurrence risk;
- and improve survival in appropriately selected intermediate- and high-risk patients.
ADT also adds its own side effects, including:
- hot flashes;
- loss of libido and erectile function;
- fatigue;
- loss of muscle mass;
- weight and metabolic changes;
- bone loss;
- and possible cardiovascular considerations.
That is why low- and favorable intermediate-risk patients should not receive ADT automatically.
ADT is part of the radiation prescription in higher-risk disease—not a generic add-on for every patient. Its duration should match recurrence risk and the patient’s metabolic, cardiovascular, bone and quality-of-life considerations.
04What Are the Side Effects and Recovery Trade-Offs of Prostate Radiation?
Radiation side effects are often delayed rather than immediate
Unlike surgery, radiation does not create a large wound or remove the prostate.
Instead, symptoms often accumulate gradually during treatment as normal tissues within or near the radiation field become inflamed.
Side effects are often divided into:
- acute effects — during treatment or shortly afterward;
- late effects — months to years later.
What urinary symptoms can occur?
Radiation can irritate the bladder neck, urethra and prostate.
Possible symptoms include:
- urinary frequency;
- urgency;
- burning with urination;
- weaker stream;
- nocturia;
- and temporary worsening of pre-existing lower urinary tract symptoms.
Later complications can include:
- persistent irritative symptoms;
- urethral stricture;
- hematuria from radiation cystitis;
- and less commonly significant urinary incontinence.
Why is baseline urinary function especially important for brachytherapy?
Brachytherapy places a high radiation dose directly through the prostate and around the urethra.
Patients who already have major urinary obstruction, poor flow or significant irritative symptoms can have a more difficult urinary recovery.
That is why current EAU guidance repeatedly specifies good urinary function when recommending LDR or HDR brachytherapy.
What bowel symptoms can occur?
The rectum sits immediately behind the prostate.
Possible acute effects include:
- increased bowel frequency;
- looser stool;
- rectal urgency;
- discomfort;
- and occasional bleeding.
Most acute symptoms improve after treatment, but late radiation proctitis, chronic rectal bleeding or altered bowel function can occur in a minority of patients.
How does radiation affect erections?
Erectile dysfunction after radiation often develops more gradually than after prostatectomy.
Radiation can affect:
- penile blood vessels;
- neurovascular structures;
- the penile bulb and surrounding tissues;
- and, when ADT is used, libido and testosterone-dependent sexual function.
The risk increases with age, baseline erectile dysfunction, vascular disease and time since treatment.
What do long-term randomized patient-reported outcomes show?
The ProtecT randomized trial provides a useful long-term comparison, although its radiation technique and hormone regimen reflect the era in which participants were treated.
Among survivors followed 7 to 12 years:
- urinary pad use remained substantially more common after prostatectomy than after radiotherapy;
- sexual function was impaired by both treatments over time;
- and bowel leakage occurred more often in the radiotherapy group in later follow-up.
At year 12, fecal leakage once per week or more was reported in 12% of the radiotherapy group compared with 6% in the prostatectomy and active-monitoring groups.
These results describe long-term trade-offs rather than a prediction for an individual patient treated with current image-guided techniques.
Can radiation cause a second cancer?
Pelvic radiation is associated with a small long-term increase in some secondary malignancies, particularly bladder or gastrointestinal cancers.
The absolute risk for an individual depends on age, smoking history, radiation technique, dose distribution and length of survival after treatment.
Can radiation cause fatigue?
Yes.
Fatigue can develop during a multiweek EBRT course.
If ADT is given at the same time, hormonal treatment can contribute independently to fatigue, hot flashes, muscle loss and sexual changes.
| Domain | During / soon after radiation | Months to years later | Important modifiers |
|---|---|---|---|
| Urinary | Frequency, urgency, burning, nocturia, weaker stream. | Persistent irritative symptoms, stricture, hematuria; severe incontinence is less common than after prostatectomy. | Baseline LUTS, prostate size, brachytherapy, prior TURP, urethral dose. |
| Bowel | Loose stool, urgency, rectal discomfort, temporary bleeding. | Chronic proctitis, bleeding or bowel-function changes in a minority. | Rectal dose, image guidance, anatomy, prior bowel disease. |
| Sexual | May initially be preserved unless ADT is used. | Erectile function can decline gradually over years. | Age, baseline erections, vascular health, ADT, dose to erectile structures. |
| Hormonal | Only when ADT is part of treatment: hot flashes, fatigue, libido loss. | Metabolic, bone and body-composition effects with longer courses. | ADT duration, baseline cardiovascular/metabolic/bone health. |
| Secondary malignancy | Not an acute issue. | Small long-term increase in some bladder/GI cancers. | Age at treatment, smoking, dose distribution, survival duration. |
Severe bleeding, inability to urinate, fever, rapidly worsening pelvic pain or other major deterioration should not be assumed to be a routine radiation effect. Acute obstruction, infection, significant bleeding and other complications require clinical assessment.
05How Is Cancer Control Monitored After Radiation Therapy?
PSA behaves differently after radiation than after prostatectomy
After radical prostatectomy, essentially all prostate tissue has been removed, so PSA is expected to become undetectable.
After radiation, the prostate remains in the body.
Normal prostate cells can continue producing PSA even when the cancer has been controlled.
Therefore:
successful radiation does not require an immediately undetectable PSA.
How fast should PSA fall?
PSA usually falls gradually.
EAU follow-up guidance notes that the PSA nadir can take up to three years or more after radiation.
A lower nadir is generally associated with a more favorable outcome, but the exact meaning of one PSA value depends on:
- the radiation modality;
- whether ADT was used;
- time since treatment;
- and the PSA trend over repeated measurements.
What is a PSA bounce?
Some patients experience a temporary rise in PSA during the first few years after radiation—particularly after brachytherapy—followed by another decline.
This phenomenon is often called a PSA bounce.
A small temporary rise does not automatically mean recurrence.
How is biochemical recurrence commonly defined after radiation?
The established Phoenix definition uses:
PSA nadir + 2 ng/mL.
In other words, biochemical failure is defined when PSA rises more than 2 ng/mL above the lowest post-radiation PSA level.
Current EAU guidance still uses this definition, including in patients who also received ADT.
Does every smaller PSA rise have to be ignored until the Phoenix threshold is reached?
No.
PSMA PET and modern imaging can sometimes identify recurrence before PSA has reached nadir + 2 ng/mL.
If an earlier investigation would change management, clinicians can evaluate a concerning PSA trend before formal biochemical-failure criteria are met.
What happens if cancer recurs after radiation?
The next step depends on whether recurrence is:
- localized within the prostate;
- in regional lymph nodes;
- or metastatic.
Selected local recurrences can sometimes be treated with salvage prostatectomy, salvage brachytherapy, stereotactic re-irradiation, cryotherapy or other local approaches in experienced centres.
However, salvage treatment after prior radiation can carry greater risks of:
- incontinence;
- urinary stricture;
- fistula;
- rectal injury;
- and other complications;
because tissues have already received substantial radiation dose.
Does radiation give the same whole-gland pathology information as surgery?
No.
One major structural difference between surgery and radiation is that radiation leaves the gland in place.
There is no postoperative whole-prostate specimen showing:
- final pathological T stage;
- complete surgical-margin status;
- or whole-gland tumor architecture.
Radiation follow-up therefore relies much more heavily on PSA trajectory, symptoms and imaging when clinically indicated.
Is radiation less effective than surgery because the prostate remains?
No.
The presence of the prostate after radiation is not evidence that cancer has not been treated.
Randomized evidence in localized prostate cancer shows low prostate-cancer mortality after both prostatectomy and radiotherapy, with distinct functional trade-offs rather than a universal oncological winner for all patients.
The broader comparison belongs in Prostate Cancer Treatment.
| Follow-up feature | After radiation therapy | After radical prostatectomy |
|---|---|---|
| Prostate gland | Remains in place. | Removed. |
| Expected PSA | Falls gradually to a nadir; not necessarily undetectable. | Expected to become undetectable. |
| Time to PSA nadir | Can take years. | Usually reaches very low/undetectable levels within weeks to months. |
| Biochemical recurrence concept | Classically nadir + 2 ng/mL (Phoenix definition). | Any confirmed postoperative rise is interpreted in the surgical follow-up framework. |
| PSA bounce | Can occur and may be benign. | Not a typical post-prostatectomy phenomenon. |
| Whole-gland pathology | No surgical specimen. | Final stage, margins and whole-gland pathology available. |
A post-radiation PSA should not be interpreted with post-prostatectomy rules. The gland remains, PSA falls more slowly and small temporary rises can occur. Trend, nadir, time since treatment, ADT exposure and modern imaging all influence interpretation.
→Radiation Therapy Options by Clinical Situation
| Clinical situation | Radiation approach | ADT role | Important selection issue |
|---|---|---|---|
| Low-risk localized | Hypofractionated EBRT or selected LDR/HDR brachytherapy if active treatment is chosen. | Generally not routine. | First determine whether active surveillance avoids unnecessary treatment. |
| Favorable intermediate-risk | Moderate/ultra-hypofractionated EBRT, LDR seed implant or HDR implant in suitable patients. | Generally not routine. | Urinary function and prostate anatomy are especially important for brachytherapy. |
| Unfavorable intermediate-risk | EBRT or EBRT + LDR/HDR brachytherapy boost in selected patients. | Short-course, commonly 4–6 months. | Balance oncological intensification against hormonal and urinary toxicity. |
| High-risk localized | IMRT/VMAT + IGRT, with brachytherapy boost in selected patients; pelvic nodes may be considered. | Long-course, commonly 18–36 months / 2–3 years depending on guideline framework. | Multimodal treatment is usually required. |
| Locally advanced / selected node-positive M0 | Prostate ± pelvic EBRT as part of multimodal treatment. | Long-term ADT; selected patients may need additional systemic intensification. | Stage, nodal status and systemic-risk features drive treatment field and duration. |
| Post-prostatectomy recurrence | Salvage radiation to prostate bed ± pelvic nodes depending on recurrence risk. | Risk-adapted; may be added in selected patients. | Different intent and anatomy from primary definitive prostate radiation. |
Key Points
- Radiation therapy is a standard curative local treatment for selected localized and locally advanced prostate cancer.
- Modern EBRT generally uses IMRT or VMAT with image guidance.
- Moderate hypofractionation shortens treatment while maintaining cancer control in appropriate patients.
- SBRT is an ultra-hypofractionated form of EBRT used in selected patients.
- Proton therapy is another form of EBRT and is not proven universally superior to modern photon IMRT/VMAT for prostate cancer.
- LDR brachytherapy leaves permanent radioactive seeds inside the prostate.
- HDR brachytherapy uses temporary catheters and removes the radiation source after each treatment.
- Good baseline urinary function is particularly important when selecting brachytherapy.
- Low- and favorable intermediate-risk disease often does not require ADT with definitive radiation.
- Unfavorable intermediate-risk disease commonly adds approximately 4–6 months of ADT.
- High-risk localized disease generally combines EBRT with long-course ADT.
- Brachytherapy boost can intensify local dose in selected unfavorable intermediate- and high-risk disease but can increase urinary toxicity.
- Urinary irritation, bowel symptoms and fatigue commonly appear during or shortly after treatment.
- Erectile dysfunction often develops more gradually after radiation than after prostatectomy.
- Long-term rectal bleeding, urinary stricture and second malignancy are uncommon but clinically important late risks.
- The prostate remains after radiation, so PSA is not expected to become immediately undetectable.
- PSA can take years to reach its lowest post-treatment level.
- A temporary PSA bounce can occur and does not automatically mean recurrence.
- The classic biochemical-recurrence definition after radiation is PSA nadir + 2 ng/mL.
- Radiation and surgery have different toxicity and follow-up patterns; neither is universally the preferred treatment for every patient.
Clinical bottom line: prostate-cancer radiation is a family of treatments rather than one fixed prescription. External-beam radiation uses precisely shaped beams delivered from outside the body, while brachytherapy places the radiation source inside the prostate. The correct plan depends on cancer risk, stage, urinary function and whether hormonal therapy should be added. Modern hypofractionation can substantially shorten EBRT schedules, and brachytherapy can serve as monotherapy or a dose-escalating boost in selected patients. As risk rises from favorable localized disease to unfavorable intermediate- and high-risk cancer, treatment generally intensifies from radiation alone toward radiation plus ADT and sometimes broader fields or brachytherapy boost. The central trade-off is cancer control versus urinary, bowel, sexual and hormonal toxicity. After treatment, PSA must be interpreted according to radiation-specific rules because the prostate remains in place and PSA declines slowly rather than becoming immediately undetectable.
Medical disclaimer: This article provides general medical education about prostate-cancer radiation therapy. The correct radiation modality, treatment field, fractionation, use of brachytherapy, ADT duration, nodal treatment and toxicity-reduction measures depend on stage, Grade Group, PSA, imaging, urinary function, prostate size, anatomy, prior procedures, life expectancy, comorbidity and treatment-centre expertise. Individual treatment should be planned with a radiation oncologist and multidisciplinary prostate-cancer team.
For the full management framework, return to Prostate Cancer Treatment. The preceding guide covers Robotic Prostatectomy. The next guide focuses specifically on External-Beam Radiation Therapy for Prostate Cancer. Long-term urinary, bowel, sexual and cancer follow-up is covered in Prostate Cancer Survivorship. For the broader disease framework, return to the Prostate Cancer hub.
Evidence Sources
- European Association of Urology — Prostate Cancer Treatment: IMRT/VMAT + IGRT, hypofractionation, SBRT, LDR/HDR brachytherapy, brachytherapy boost, ADT duration and risk-adapted radiation recommendations.
- European Association of Urology — Prostate Cancer Follow-up: PSA decline after radiotherapy, time to nadir and Phoenix biochemical-recurrence definition.
- AUA/ASTRO — Clinically Localized Prostate Cancer Guideline: hypofractionated EBRT, LDR/HDR brachytherapy, ADT by risk group, pelvic-node treatment and shared treatment selection.
- ASTRO/ASCO/AUA — Hypofractionated Radiation Therapy for Localized Prostate Cancer: moderate and ultra-hypofractionation principles and patient selection.
- National Cancer Institute — Prostate Cancer Treatment PDQ, Health Professional Version: external-beam radiation, brachytherapy, complications and stage-based treatment context.
- National Cancer Institute — Brachytherapy to Treat Cancer: internal radiation principles and placement of radioactive sources near or within tumor tissue.
- ProtecT Study Group — 12-year patient-reported outcomes after active monitoring, prostatectomy or radiotherapy, including long-term urinary, sexual and bowel trade-offs.
